| Autor: |
Li CY; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing100730, China., Teng LR; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing100730, China., Lin Q; Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, Beijing100050, China., Zhao LP; Department of Women's Health, Beijing Daxing District Maternal and Child Health Care Hospital, Beijing102600, China., Zhu YX; Department of Obstetrics, Beijing Youan Hospital, Capital Medical University, Beijing100069, China., Mi X; Department of Reproductive Regulation, Shunyi Women's and Children's Hospital of Beijing Children's Hospital, Beijing101300, China., Wang ZN; Department of Reproductive Regulation, Shunyi Women's and Children's Hospital of Beijing Children's Hospital, Beijing101300, China., Wang XY; Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing100191, China., Zhang LS; Department of Gynecology, Fu Xing Hospital, Capital Medical University, Beijing100038, China., Han D; Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital Medical University, Beijing100070, China., Ma LL; Department of Obstetrics and Gynecology, Beijing Daxing District People's Hospital, Beijing102600, China., Bai WP; Department of Gynecology, Beijing Shijitan Hospital, Capital Medical University, Beijing100038, China., Wang JM; Department of Family Planning, The Second Hospital of Tianjin Medical University, Tianjin300211, China., Ni J; Department of Obstetrics and Gynecology, Beijing Haidian Hospital, Beijing100080, China., Shen HP; Department of Family Planning Service, Beijing Haidian District Maternal and Child Health Care Hospital, Beijing100080, China., Chen QF; Department of Family Planning, The International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University School of Medicine, Shanghai200030, China., Xu HM; Department of Obstetrics and Gynecology, Beijing Fengtai Hospital, Beijing100071, China., Ren CC; Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China., Jiang J; Department of Obstetrics and Gynecology, The Second Hospital of Heibei Medical University, Shijiazhuang050000, China., Liu GY; Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing100020, China., Peng P; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing100730, China., Liu XY; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing100730, China. |
| Abstrakt: |
Objective: To evaluate the impact of self-crosslinked hyaluronic acid (SCH) gel on endometrium recovery after artificial abortion. Methods: A multicenter, prospective randomized controlled trial was conducted across 18 hospitals from December 2021 to February 2023, involving 382 women who underwent artificial abortion. Participants were randomly allocated to receive either treatment with SCH gel (SCH group) or no treatment (control group) in a 1∶1 ratio. The primary outcome was endometrium thickness in 14 to 18 days after the first postoperative menstruation. Secondary outcomes included changes in menstrual volume during the first postoperative menstruation, menstruation resumption within 6 postoperative weeks, time to menstruation resumption, duration of the first postoperative menstruation, and incidence of dysmenorrhea. Results: Baseline characteristics of participants were comparable between the two groups (all P >0.05), with 95.3% (182/191) in SCH group and 92.7% (177/191) in the control group completed the study. The postoperative endometrial thickness in SCH group was significantly greater than that in the control group [(9.78±3.15) vs (8.95±2.32) mm; P =0.005]. SCH group also had significantly fewer participants with reduced menstrual volume [23 cases (12.6%, 23/182) vs 31 cases (17.5%, 31/177); P =0.038]. Although SCH group experienced less dysmenorrhea during the first postoperative menstrual period, this difference was not statistically significant [28.5% (51/179) vs 37.1% (65/175); P =0.083]. Outcomes were similar between SCH group and the control group regarding the proportion of participants who resumed menstruation within 6 weeks postoperatively, time to menstruation resumption, and duration of the first postoperative menstruation ( P =0.792, 0.485, and 0.254, respectively). No serious adverse events were observed during the study period, and no adverse events were attributed to SCH gel treatment. Conclusion: The application of SCH gel after artificial abortion is safe and might aid in the recovery of the endometrium. |
